

Saturday, July 12, 2025

	Room A (Kairaku 1+2)	Room B (Kairaku 3)	Poster
7:00			
8:00	7:30-8:20 Breakfast Symposium 1 Reconsidering the future use of drug therapy in the era of combined immunotherapy <i>Sponsored by Eisai Co., Ltd.</i>		
	8:30-8:40	Opening Ceremony	
9:00	8:45-9:15 State of the Art Lecture 1.		
	9:15-10:30	9:15-10:30	9:00-18:00
10:00	Session 1a. Epidemiology and Medical Circumstance for HCC in Asian-Pacific region	Session 1b. Epidemiology and Basic Science / Translational Research in CCA	
	10:30-10:45 Coffee Break		
11:00	10:45-12:05	10:45-12:05	
	Session 2a. Molecular Pathogenesis and Pathology in HCC	Session 2b. Locoregional Therapy for CCA	
12:00			
	12:30-13:20 Luncheon Symposium 1 The role of lenvatinib, synthesized in Japan, in the treatment of hepatocellular carcinoma <i>Sponsored by Eisai Co., Ltd.</i>	12:30-13:20 Luncheon Symposium 2 Advancing the Frontier: Systemic Therapy in Challenging HCC <i>Sponsored by Roche</i>	Poster Viewing
13:00			
	13:30-14:00 State of the Art Lecture 2.		
14:00	14:00-15:15	14:00-15:15	
	Session 3a. Surgery, and Liver Transplant for HCC	Session 3b. Systemic Therapy for CCA	
15:00			
	15:20-15:50 State of the Art Lecture 3.		
16:00	15:50-16:00 Coffee Break		
			16:00-17:00
17:00			Poster Presentation Session
	17:10-18:30	17:10-18:30	
18:00	Session 4a. Locoregional Therapy for HCC	Session 4b. Rare Liver Tumors	
19:00			
20:00	19:00-21:00 GALA Dinner (APPLE General Meeting)		
21:00			